IMA vs SRZN vs IMVT vs KYMR vs ARQT

For growth investors, Arcutis Biotherapeutics, Inc.

(ARQT) is the stronger pick with 91. 3% revenue growth year-over-year, versus -77. 1% for ImageneBio Inc (IMA). Analysts rate Surrozen, Inc. (SRZN) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Immunovant, Inc.

(IMVT) delivered a total return of +213. 0%, compared to -96. 7% for ImageneBio Inc (IMA). Over 10 years, the gap is even starker: IMVT returned +237. 9% versus IMA's -98. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), ImageneBio Inc (IMA) is the lower-risk stock at 0.

83β versus Immunovant, Inc. 's 1. 66β — meaning IMVT is approximately 99% more volatile than IMA relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 8% for ImageneBio Inc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Arcutis Biotherapeutics, Inc.

(ARQT) is pulling ahead at 91. 3% versus -77. 1% for ImageneBio Inc (IMA). On earnings-per-share growth, the picture is similar: Arcutis Biotherapeutics, Inc. grew EPS 88. 8% year-over-year, compared to -954. 9% for ImageneBio Inc. Over a 3-year CAGR, ARQT leads at 367. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Immunovant, Inc.

(IMVT) is the more profitable company, earning 0. 0% net margin versus -69. 6% for Surrozen, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IMVT leads at 0. 0% versus -60. 6% for IMA. At the gross margin level — before operating expenses — KYMR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for SRZN: 79.

6% to $42. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Kymera Therapeutics, Inc.

(KYMR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 91), +159. 2% 10Y return). Immunovant, Inc. (IMVT) carries a higher beta of 1. 66 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KYMR: +159. 2%, IMVT: +237. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: IMA is a small-cap quality compounder stock; SRZN is a small-cap quality compounder stock; IMVT is a small-cap quality compounder stock; KYMR is a small-cap quality compounder stock; ARQT is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.